Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT05176535 Recruiting - Clinical trials for Microbial Colonization

Determination of Vaginal Colonization and the Effect of an Oral Probiotic (PROSALVAG)

PROSALVAG
Start date: October 11, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to determine the efficacy of an oral nutraceutical with probiotics in restore vaginal health.

NCT ID: NCT05175768 Recruiting - COVID-19 Infection Clinical Trials

Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection

Start date: December 27, 2021
Phase: N/A
Study type: Interventional

A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated with COVID-19 Infection

NCT ID: NCT05172089 Recruiting - Diabetic Foot Clinical Trials

Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence

DFUBiofilm
Start date: April 2, 2024
Phase:
Study type: Observational

Diabetic foot ulcers (DFU) are one of the most common reasons for hospitalization of diabetic patients and frequently results in amputation of lower limbs. Of the one million people who undergo non-traumatic leg amputations annually worldwide, 75% are performed on people who have type 2 diabetes (T2DM). The risk of death at 10 years for a diabetic with DFU is twice as high as the risk for a patient without a DFU. The rate of amputation in patients with DFU is 38.4%4. Infection is a common (>50%) complication of DFU. Emerging evidence underscores the significant risk that biofilm infection poses to the non-healing DFU. Biofilms are estimated to account for 60% of chronic wound infections. In the biofilm form, bacteria are in a dormant metabolic state. Thus, standard clinical techniques like the colony forming unit (CFU) assay to detect infection may not detect biofilm infection. Thus, biofilm infection may be viewed as a silent maleficent threat in wound care.

NCT ID: NCT05169229 Recruiting - Osteoarthritis, Hip Clinical Trials

Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.

ABOGRAFT
Start date: April 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Total hip replacement is the most successful treatment modern healthcare can offer patients to regain quality of life. Periprosthetic joint infection (PJI) is the most common and devastating complication after total hip replacement (THR). Between 0.5 to 2% of primary THR (first time hip replacement), and 8-10% of revision THR (replacement of a hip prosthesis) will become infected.1 The introduction of local antibiotics blended into bone cement has led to a reduction in postoperative infection in primary THR by half.2 Unfortunately, cement can't always be used in relevant quantities. The number of primary and revision surgeries of the hip is projected to increase dramatically. Therefore, the need for a feasible infection prophylaxis that is applicable for complex primary and revision THR in addition to antibiotics loaded cement is urgent. Impacted morselized bone allograft is often used in (revision) THR to fill bone defects. Morselized allograft has been used as a carrier for local antibiotic treatment in multiple pilot studies and appears to be an attractive and effective treatment option, both for already infected joints and as a prophylactic measure in high-risk patients (e.g. THR revision surgeries). Nonetheless, a pivotal trial to support its use in THR is lacking. The aim of this pragmatic randomized controlled double blinded drug trial is to investigate whether antibiotic impregnated bone graft (AIBG) decreases the risk of infection after hip arthroplasty compared to controls treated with placebo impregnated bone graft. Patients scheduled for elective THR will be randomized to receive AIBG or a placebo impregnated bone graft. The primary outcome variable will be the number of re-operations due to infections and PJI diagnoses 2 years postoperative.

NCT ID: NCT05164744 Recruiting - COVID-19 Clinical Trials

Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors

Start date: July 1, 2021
Phase:
Study type: Observational

The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.

NCT ID: NCT05153694 Recruiting - Bladder Cancer Clinical Trials

Infectious Complications After Cystectomy: A Prospective Observational Study

Start date: December 1, 2021
Phase:
Study type: Observational

In this study, we evaluate peri- and postoperative parameters of patients undergoing a cystectomy and try to find risk factors for infectious complications. In detail, we analyze their medical history, demographic data, lab values, microbiological tests as well as histological and radiological findings. Furthermore, after discharging our patients, we send them several follow-up questionnaires at regular intervals and offer them free follow-up examinations.

NCT ID: NCT05153005 Recruiting - Clinical trials for Opportunistic Fungal Infections

Comprehensive Diagnosis and Treatment Strategy for Opportunistic Fungal Infections in AIDS Patients

Start date: April 1, 2021
Phase:
Study type: Observational

Opportunistic fungal infection is the most common opportunistic infection in AIDS patients, with the high mortality and recurrence rate due to the lack of standardized comprehensive diagnosis and treatment strategy. This project aims to combine traditional detection and observation indicators with molecular biology, serology and mass spectrometry identification technology to develop early screening and diagnostic strategies for opportunistic fungal infections in AIDS patients, explore scientific evaluation methods for anti-fungal efficacy and formulate comprehensive strategies for reducing the mortality and recurrence rate.

NCT ID: NCT05150327 Recruiting - Fungal Infection Clinical Trials

Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients

FongiFoie
Start date: November 1, 2021
Phase:
Study type: Observational

Invasive filamentous fungal infections (aspergillosis, scedosporiosis, mucormycosis, fusarium wilt) are frequent and serious in immunocompromised individuals and especially in organ transplant patients. There is little recent data in liver transplantation, especially on the incidence and risk factors of fungal infections

NCT ID: NCT05148702 Recruiting - Clinical trials for Complicated Intra-abdominal Infection

EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.

EXTEND
Start date: October 10, 2022
Phase: Phase 3
Study type: Interventional

A multicentre, open label, two-arm, parallel group, pragmatic, randomised controlled trial with internal pilot. A total of 1166 consenting adult patients with cIAI will be recruited and randomised on a 1:1 basis between 28-days antibiotics and standard care antibiotics. Patients will be followed up for 180 days to determine cost effectiveness and the rate of treatment failure in each group.

NCT ID: NCT05147519 Recruiting - HIV Infections Clinical Trials

Protocol RV 583 Multinational Observational Cohort of HIV and Other Infections

MOCHI
Start date: November 5, 2021
Phase:
Study type: Observational

Multinational Observational Cohort of HIV and other Infections (MOCHI). This observational study is to gain information regarding the number of new HIV infections among people who engage in behaviors that make them vulnerable to acquiring HIV across multiple international sites.